Recycling stock with strong future growth guidance to keep on your radarRecycling stock with strong future growth guidance to keep on your radar

Introduction:

This recycling stock is focused on significant future growth, backed by strategic investments and a robust market position. Its outlook remains positive, with a commitment to sustainability and operational efficiency. 

Also Read: Shipping stocks to benefit after FM announces ₹25,000 Cr financial assistance to boost shipbuilding sector

Dr. Reddy’s Laboratories Ltd

Dr. Reddy’s Laboratories Ltd is a global pharmaceutical company known for its generic medicines and active pharmaceutical ingredients. It focuses on providing affordable healthcare solutions across various therapeutic areas. 

Share price movement: 

On February 1, 2025, Dr. Reddy’s Laboratories Ltd (BSE: DRREDDY) opened at ₹1,225.10, reached a high of ₹1,225.10, and a low of ₹1,200.05. The stock closed at ₹1,205.30, down by 1.01%, with a market cap of ₹1,00,568.41 Cr.

Future guidance

Dr. Reddy’s laboratories expects continued growth in its revenue and profit margins, driven by new product launches and strategic acquisitions. The NRT business is anticipated to contribute positively, starting in April 2025. 

In the coming quarters, the company plans to overcome challenges in the cardiac and gastrointestinal segments with strategic adjustments. The successful integration of NRT, combined with continued growth in emerging markets, is expected to drive long-term profitability. 

The company’s outlook remains positive, with a strong emphasis on biosimilars and innovative products as growth drivers. Investments in R&D and sustainability initiatives are expected to strengthen their position in global rankings. 

Also Read: What is the policy announced by FM for footwear sector in union budget 2025?

Projects & Performance update: 

Progress on biosimilars is advancing, with Rituximab receiving Marketing Authorisation in the UK and Denosumab filings in the US and Europe. The company is focusing on selective products in the biosimilar market to capture value in a competitive landscape.

The integration of the newly acquired NRT business will begin in April 2025. Ongoing collaborations with Haleon for distribution services will ensure a smooth transition and operational efficiency. This is expected to open new avenues for growth.

In Q3FY25, the company reported consolidated revenues of ₹8,359 crores, reflecting a 16% YoY growth. The growth was driven by the NRT business acquisition, adding ₹605 crores. However, underlying growth was 7.5% YoY, with a slight decline in QoQ performance.

Shareholding pattern of Dr Reddys Laboratories: 

All values in %	Dec 2024	Sep 2024	Jun 2024
Promoter	26.6	26.6	26.7
FII	26.9	27.5	27.7
DII	36.1	35.7	35.3
Public	10.2	10.0	10.2

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.